Dr Lal Pathlabs vs Syngene Intl.
Side-by-side stock comparison based on AI earnings call analysis
Which stock has stronger management signals?
Both companies need to be compared on revenue growth quality, margin trajectory and management commentary.
Dr Lal Pathlabs show active capex signals based on earnings call analysis.
No strong fundraising signal is currently visible for either company.
| Metric | Dr Lal Pathlabs | Syngene Intl. |
|---|---|---|
| Current Price | ₹1,859.9 | ₹386.1 |
| Market Cap | ₹31,218.2 Cr. | ₹15,585.67 Cr. |
| Industry | Healthcare Services | Healthcare Services |
| P/E Ratio | 55.53 | 52.63 |
| ROE (%) | 22.3 | 7.78 |
| Debt/Equity | 0.08 | 0.09 |
| Sales Growth 5Y (%) | 11.81 | 11.35 |
| Profit Growth 5Y (%) | 29.43 | -13.17 |
| Promoter Holding (%) | 52.93 | 52.59 |
| Revenue Rank | Rank 3 | No information |
| Margin Rank | Rank 3 | No information |
| Signal | — | — |
| Capex | Yes | No information |
| Fundraise | No information | No information |